aluates Reports

$ 0.0

Automative

Acute Myeloid Leukemia (AML) Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: September 2024

Report Code: QYRE-Auto-19U13394

Global Acute Myeloid Leukemia AML Therapeutics Market Research Report 2023

BUY CHAPTERS

Acute Myeloid Leukemia (AML) Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-19U13394

Report

September 2024

Pages:92

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Bristol–Myers Squibb

Novartis

Roche

Genmab

GlaxoSmithKline Pharmaceuticals

Acute Myeloid Leukemia (AML) Therapeutics - Market Size

Therapeutics was estimated to be worth US$ 543.8 million in 2023 and is forecast to a readjusted size of US$ 1145.5 million by 2030 with a CAGR of 11.0% during the forecast period 2024-2030

Acute Myeloid Leukemia (AML) Therapeutics - Market

The global market for Acute Myeloid Leukemia (AML)

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia (AML) Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Acute Myeloid Leukemia (AML) Therapeutics by region & country, by Type, and by Application.

The Acute Myeloid Leukemia (AML) Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia (AML) Therapeutics.

Market Segmentation

Scope of Acute Myeloid Leukemia (AML) Therapeutics - Market Report

Report Metric	Details
Report Name	Acute Myeloid Leukemia (AML) Therapeutics - Market
Forecasted market size in 2030	US$ 1145.5 million
CAGR	11.0%
Forecasted years	2024 - 2030
Segment by Type:	Chemotherapy Radiation therapy Stem Cell Transplant Targeted Therapy Others
Segment by Application	Hospital Clinics Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bristol-Myers Squibb, Novartis, Roche, Genmab, GlaxoSmithKline Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Acute Myeloid Leukemia (AML) Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Acute Myeloid Leukemia (AML) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Acute Myeloid Leukemia (AML) Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Acute Myeloid Leukemia (AML) Therapeutics - Market size in 2030?

Ans: The Acute Myeloid Leukemia (AML) Therapeutics - Market size in 2030 will be US$ 1145.5 million.

Who are the main players in the Acute Myeloid Leukemia (AML) Therapeutics - Market report?

Ans: The main players in the Acute Myeloid Leukemia (AML) Therapeutics - Market are Bristol-Myers Squibb, Novartis, Roche, Genmab, GlaxoSmithKline Pharmaceuticals

What are the Application segmentation covered in the Acute Myeloid Leukemia (AML) Therapeutics - Market report?

Ans: The Applications covered in the Acute Myeloid Leukemia (AML) Therapeutics - Market report are Hospital, Clinics, Others

What are the Type segmentation covered in the Acute Myeloid Leukemia (AML) Therapeutics - Market report?

Ans: The Types covered in the Acute Myeloid Leukemia (AML) Therapeutics - Market report are Chemotherapy, Radiation therapy, Stem Cell Transplant, Targeted Therapy, Others

Recommended Reports

Leukemia Treatments

Cancer Therapeutics

Solid Tumor Treatments

1 Market Overview

1.1 Acute Myeloid Leukemia (AML) Therapeutics Product Introduction

1.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size Forecast

1.3 Acute Myeloid Leukemia (AML) Therapeutics Market Trends & Drivers

1.3.1 Acute Myeloid Leukemia (AML) Therapeutics Industry Trends

1.3.2 Acute Myeloid Leukemia (AML) Therapeutics Market Drivers & Opportunity

1.3.3 Acute Myeloid Leukemia (AML) Therapeutics Market Challenges

1.3.4 Acute Myeloid Leukemia (AML) Therapeutics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Players Revenue Ranking (2023)

2.2 Global Acute Myeloid Leukemia (AML) Therapeutics Revenue by Company (2019-2024)

2.3 Key Companies Acute Myeloid Leukemia (AML) Therapeutics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Acute Myeloid Leukemia (AML) Therapeutics Product Offered

2.5 Key Companies Time to Begin Mass Production of Acute Myeloid Leukemia (AML) Therapeutics

2.6 Acute Myeloid Leukemia (AML) Therapeutics Market Competitive Analysis

2.6.1 Acute Myeloid Leukemia (AML) Therapeutics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Acute Myeloid Leukemia (AML) Therapeutics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia (AML) Therapeutics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Chemotherapy

3.1.2 Radiation therapy

3.1.3 Stem Cell Transplant

3.1.4 Targeted Therapy

3.1.5 Others

3.2 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type

3.2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value, by Type (2019-2030)

3.2.3 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinics

4.1.3 Others

4.2 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application

4.2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value, by Application (2019-2030)

4.2.3 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Region

5.1.1 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Region (2019-2024)

5.1.3 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Region (2025-2030)

5.1.4 Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019-2030

5.2.2 North America Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019-2030

5.3.2 Europe Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019-2030

5.4.2 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019-2030

5.5.2 South America Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019-2030

5.6.2 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Acute Myeloid Leukemia (AML) Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Acute Myeloid Leukemia (AML) Therapeutics Sales Value

6.3 United States

6.3.1 United States Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019-2030

6.3.2 United States Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019-2030

6.4.2 Europe Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019-2030

6.5.2 China Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.5.3 China Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019-2030

6.6.2 Japan Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019-2030

6.7.2 South Korea Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019-2030

6.8.2 Southeast Asia Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019-2030

6.9.2 India Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

6.9.3 India Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Bristol-Myers Squibb

7.1.1 Bristol-Myers Squibb Profile

7.1.2 Bristol-Myers Squibb Main Business

7.1.3 Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Products, Services and Solutions

7.1.4 Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Revenue (US$ Million) & (2019-2024)

7.1.5 Bristol-Myers Squibb Recent Developments

7.2 Novartis

7.2.1 Novartis Profile

7.2.2 Novartis Main Business

7.2.3 Novartis Acute Myeloid Leukemia (AML) Therapeutics Products, Services and Solutions

7.2.4 Novartis Acute Myeloid Leukemia (AML) Therapeutics Revenue (US$ Million) & (2019-2024)

7.2.5 Novartis Recent Developments

7.3 Roche

7.3.1 Roche Profile

7.3.2 Roche Main Business

7.3.3 Roche Acute Myeloid Leukemia (AML) Therapeutics Products, Services and Solutions

7.3.4 Roche Acute Myeloid Leukemia (AML) Therapeutics Revenue (US$ Million) & (2019-2024)

7.3.5 Genmab Recent Developments

7.4 Genmab

7.4.1 Genmab Profile

7.4.2 Genmab Main Business

7.4.3 Genmab Acute Myeloid Leukemia (AML) Therapeutics Products, Services and Solutions

7.4.4 Genmab Acute Myeloid Leukemia (AML) Therapeutics Revenue (US$ Million) & (2019-2024)

7.4.5 Genmab Recent Developments

7.5 GlaxoSmithKline Pharmaceuticals

7.5.1 GlaxoSmithKline Pharmaceuticals Profile

7.5.2 GlaxoSmithKline Pharmaceuticals Main Business

7.5.3 GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Products, Services and Solutions

7.5.4 GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Revenue (US$ Million) & (2019-2024)

7.5.5 GlaxoSmithKline Pharmaceuticals Recent Developments

8 Industry Chain Analysis

8.1 Acute Myeloid Leukemia (AML) Therapeutics Industrial Chain

8.2 Acute Myeloid Leukemia (AML) Therapeutics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Acute Myeloid Leukemia (AML) Therapeutics Sales Model

8.5.2 Sales Channel

8.5.3 Acute Myeloid Leukemia (AML) Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Bristol–Myers Squibb

Novartis

Roche

Genmab

GlaxoSmithKline Pharmaceuticals

List of Tables

Table 1. Acute Myeloid Leukemia (AML) Therapeutics Market Trends

Table 2. Acute Myeloid Leukemia (AML) Therapeutics Market Drivers & Opportunity

Table 3. Acute Myeloid Leukemia (AML) Therapeutics Market Challenges

Table 4. Acute Myeloid Leukemia (AML) Therapeutics Market Restraints

Table 5. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Acute Myeloid Leukemia (AML) Therapeutics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Acute Myeloid Leukemia (AML) Therapeutics Product Type

Table 9. Key Companies Time to Begin Mass Production of Acute Myeloid Leukemia (AML) Therapeutics

Table 10. Global Acute Myeloid Leukemia (AML) Therapeutics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia (AML) Therapeutics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Region (2019-2024) & (%)

Table 27. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Acute Myeloid Leukemia (AML) Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Acute Myeloid Leukemia (AML) Therapeutics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Acute Myeloid Leukemia (AML) Therapeutics Sales Value, (2025-2030) & (US$ Million)

Table 31. Bristol-Myers Squibb Basic Information List

Table 32. Bristol-Myers Squibb Description and Business Overview

Table 33. Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Acute Myeloid Leukemia (AML) Therapeutics Business of Bristol-Myers Squibb (2019-2024)

Table 35. Bristol-Myers Squibb Recent Developments

Table 36. Novartis Basic Information List

Table 37. Novartis Description and Business Overview

Table 38. Novartis Acute Myeloid Leukemia (AML) Therapeutics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Acute Myeloid Leukemia (AML) Therapeutics Business of Novartis (2019-2024)

Table 40. Novartis Recent Developments

Table 41. Roche Basic Information List

Table 42. Roche Description and Business Overview

Table 43. Roche Acute Myeloid Leukemia (AML) Therapeutics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Acute Myeloid Leukemia (AML) Therapeutics Business of Roche (2019-2024)

Table 45. Roche Recent Developments

Table 46. Genmab Basic Information List

Table 47. Genmab Description and Business Overview

Table 48. Genmab Acute Myeloid Leukemia (AML) Therapeutics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Acute Myeloid Leukemia (AML) Therapeutics Business of Genmab (2019-2024)

Table 50. Genmab Recent Developments

Table 51. GlaxoSmithKline Pharmaceuticals Basic Information List

Table 52. GlaxoSmithKline Pharmaceuticals Description and Business Overview

Table 53. GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Acute Myeloid Leukemia (AML) Therapeutics Business of GlaxoSmithKline Pharmaceuticals (2019-2024)

Table 55. GlaxoSmithKline Pharmaceuticals Recent Developments

Table 56. Key Raw Materials Lists

Table 57. Raw Materials Key Suppliers Lists

Table 58. Acute Myeloid Leukemia (AML) Therapeutics Downstream Customers

Table 59. Acute Myeloid Leukemia (AML) Therapeutics Distributors List

Table 60. Research Programs/Design for This Report

Table 61. Key Data Information from Secondary Sources

Table 62. Key Data Information from Primary Sources

Table 63. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Acute Myeloid Leukemia (AML) Therapeutics Product Picture

Figure 2. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 4. Acute Myeloid Leukemia (AML) Therapeutics Report Years Considered

Figure 5. Global Acute Myeloid Leukemia (AML) Therapeutics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Acute Myeloid Leukemia (AML) Therapeutics Revenue in 2023

Figure 7. Acute Myeloid Leukemia (AML) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Chemotherapy Picture

Figure 9. Radiation therapy Picture

Figure 10. Stem Cell Transplant Picture

Figure 11. Targeted Therapy Picture

Figure 12. Others Picture

Figure 13. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of Hospital

Figure 16. Product Picture of Clinics

Figure 17. Product Picture of Others

Figure 18. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 19. Global Acute Myeloid Leukemia (AML) Therapeutics Sales Value Market Share by Application, 2023 & 2030

Figure 20. North America Acute Myeloid Leukemia (AML) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 21. North America Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 22. Europe Acute Myeloid Leukemia (AML) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 23. Europe Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 24. Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 25. Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 26. South America Acute Myeloid Leukemia (AML) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 27. South America Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 28. Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 29. Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 30. Key Countries/Regions Acute Myeloid Leukemia (AML) Therapeutics Sales Value (%), (2019-2030)

Figure 31. United States Acute Myeloid Leukemia (AML) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 32. United States Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 33. United States Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 34. Europe Acute Myeloid Leukemia (AML) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 35. Europe Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 36. Europe Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 37. China Acute Myeloid Leukemia (AML) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 38. China Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 39. China Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 40. Japan Acute Myeloid Leukemia (AML) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 41. Japan Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 42. Japan Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 43. South Korea Acute Myeloid Leukemia (AML) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 44. South Korea Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 45. South Korea Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 46. Southeast Asia Acute Myeloid Leukemia (AML) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 47. Southeast Asia Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 48. Southeast Asia Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 49. India Acute Myeloid Leukemia (AML) Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 50. India Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 51. India Acute Myeloid Leukemia (AML) Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 52. Acute Myeloid Leukemia (AML) Therapeutics Industrial Chain

Figure 53. Acute Myeloid Leukemia (AML) Therapeutics Manufacturing Cost Structure

Figure 54. Channels of Distribution (Direct Sales, and Distribution)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Hematological Malignancy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hematological Malignancies Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Myeloid Cells Targeting Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Hematological Malignancy Treatment Market Research Report 2025

Global Acute Lymphoblastic Leukemia Drug Market Research Report 2024

Cancer Therapeutics and Biotherapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Acute Lymphocytic Leukemia ALL Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Oncology Anti cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Hairy Cell Leukemia Therapeutics Market Research Report 2024

Global Neutropenia Drugs Market Research Report 2025

AI for Cancer Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Anthracycline Anticancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Novel Drug Delivery Systems for Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Acute Myeloid Leukemia Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Non Small Cell Lung Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Medicines for Alzheimer Disease Treatment Market Research Report 2025

Global Asthma Therapeutics Market Research Report 2025

Sickle Cell Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Myelodysplastic Syndrome Drug Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions